Barrington Adjusts Price Target on Orthofix Medical to $15 From $17, Maintains Outperform Rating
Barrington Research has adjusted its price target for Orthofix Medical (NASDAQ: OFIX) shares to $15, down from the previous $17. Despite the reduction in the price target, the firm has maintained an Outperform rating on the medical device company's stock. This update reflects Barrington's continued positive outlook on Orthofix Medical's performance potential.
Stifel cuts Orthofix Medical stock price target on reimbursement hit
Stifel lowered its price target for Orthofix Medical Inc. to $15 from $18 due to reduced reimbursement rates for bone growth stimulators, following a 10% cut by CMS. Orthofix Medical has revised its 2026 revenue and adjusted EBITDA guidance downwards and no longer expects positive free cash flow this year. Despite these challenges, analysts predict the company will be profitable in 2026, with an EPS forecast of $0.96.
Orthofix Medical updates 2026 outlook after CMS Medicare cuts for bone growth stimulators
Orthofix Medical has revised its 2026 financial guidance downward following CMS Medicare reimbursement cuts for non-invasive bone growth stimulators, which are expected to reduce Medicare rates by approximately 10%. The company now projects net sales between $838M–$848M and non-GAAP adjusted EBITDA of $90M–$93M. Orthofix also suspended its three-year financial targets and does not anticipate positive free cash flow in 2026 due to these actions.
Medicare cuts push Orthofix (NASDAQ: OFIX) to lower 2026 outlook and scrap 3-year goals
Orthofix Medical Inc. (OFIX) has lowered its 2026 financial outlook and withdrawn its three-year targets due to anticipated Medicare reimbursement cuts for non-invasive bone growth stimulators. Following an FDA reclassification and CMS billing updates effective May 18, 2026, the company expects a 10% decline in average Medicare reimbursement for key codes. This change is projected to result in 2026 net sales of $838–$848 million, non-GAAP adjusted EBITDA of $90–$93 million, and no positive free cash flow for the year.
Orthofix Medical Inc stock (US6875231068): spine specialist in focus after recent setbacks and restructuring push
Orthofix Medical Inc. is undergoing a significant transformation amidst leadership changes, restructuring efforts, and softer demand in its core markets. The company, a specialist in musculoskeletal care with a focus on spine and orthopedics, reported weaker financial results for Q4 and full-year 2024. Investors are closely monitoring the success and pace of its turnaround strategy, which relies on niche product differentiation, innovation, and navigating a complex regulatory and competitive landscape.
Orthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. announced its participation in two upcoming investor conferences. The company will have a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and will hold 1x1 meetings at the Truist Securities MedTech Conference on June 16, 2026. Interested parties can access the webcast of the Goldman Sachs chat on the Orthofix Investor Relations website.
Orthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. (NASDAQ: OFIX) announced their participation in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and the Truist Securities MedTech Conference on June 16, 2026. The company will host a fireside chat at the Goldman Sachs conference, which will be webcast, and conduct 1x1 meetings at the Truist event. Investors are encouraged to visit the Orthofix Investor Relations website for more details and access to the webcast.
Orthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. announced it will participate in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and the Truist Securities MedTech Conference on June 16, 2026. A live and archived webcast of the Goldman Sachs fireside chat will be available on the Orthofix Investor Relations website.
Orthofix Medical Inc stock (US6875231068): spine specialist in focus after latest guidance and leade
Orthofix Medical Inc. is drawing renewed investor attention after updating its 2025 financial outlook and confirming leadership changes in early 2026. The company specializes in spine and orthopedic medical devices, with a business model focused on implants, hardware, and biologic solutions. Its performance is closely tied to surgical volumes, reimbursement trends, and its ability to compete in a market driven by innovation and strong surgeon relationships, particularly in the US.
Armistice Capital (OFIX) reports 2.7M shares, 6.73% stake in Orthofix
Armistice Capital, LLC and Steven Boyd have reported a shared beneficial ownership of 2.7 million shares in Orthofix Medical Inc. (OFIX), representing a 6.73% stake. This disclosure, made via an Amendment No. 7 to a Schedule 13G/A filing, indicates that Armistice Capital exercises voting and investment power over these shares, which are held by Armistice Capital Master Fund Ltd. The filing clarifies that while the Master Fund is the direct holder, it disclaims beneficial ownership due to the Investment Management Agreement.
Orthofix Medical Inc. (NASDAQ:OFIX) Given Average Rating of "Hold" by Brokerages
Orthofix Medical Inc. (NASDAQ:OFIX) has received a consensus "Hold" rating from six research firms, with an average 12-month price target of $17.25. The company recently surpassed earnings expectations, reporting an EPS of -$0.52 and revenue of $196.71 million. Insider activity shows a mix of sales and significant purchases, with institutional investors owning nearly 90% of the stock.
Orthofix Medical stock (US6875231068): Brokerages rate Hold with $17.25 target
Orthofix Medical (NASDAQ: OFIX) has received a consensus Hold rating from six brokerages, with an average 12-month price target of $17.25. The company specializes in medical technologies for spine and orthopedic conditions, with a significant focus on the US healthcare market. Its main revenue drivers are BioStim and Spinal Implants segments, and it operates in an expanding orthopedic device sector.
Orthofix Medical (DB:OM2) - Stock Analysis
Orthofix Medical Inc. (DB:OM2) is currently trading 66.1% below its estimated fair value and is considered undervalued compared to peers, with analysts projecting a 40.4% rise in stock price. However, the company is unprofitable, not expected to become profitable within the next three years, and has experienced significant insider selling. Recent announcements highlight expansions in its pediatric limb reconstruction portfolio and upcoming earnings reports, along with several changes to its executive team and board, and resolution of some legal actions.
[Form 4] Orthofix Medical Inc. Insider Trading Activity
Orthofix Medical Inc. director John B. Henneman III recently purchased 5,000 shares of common stock at a price of $12.259 per share in an open-market transaction. Following this purchase, his direct holdings in the company now stand at 90,809 shares, which includes previously reported deferred stock units and shares acquired through the company's Stock Purchase Plan. This transaction is categorized as a net buy, with a total value of $61,295.
US$17.25: That's What Analysts Think Orthofix Medical Inc. (NASDAQ:OFIX) Is Worth After Its Latest Results
Orthofix Medical Inc. (NASDAQ: OFIX) recently released its latest quarterly results, showing revenues in line with analyst predictions but smaller-than-expected statutory losses. Despite reconfirming revenue numbers, analysts increased their per-share loss estimates, leading to a 5.5% dip in the average price target to US$17.25, reflecting concerns about growing losses and a slower projected revenue growth compared to the industry average.
Engine Capital (NASDAQ: OFIX) funds add 184,896 Orthofix Medical shares in open-market buys
Funds associated with Engine Capital have purchased 184,896 shares of Orthofix Medical (NASDAQ: OFIX) through open-market transactions between May 5 and May 7, 2026. These shares were acquired at prices ranging from $11.99 to $12.23 per share, indicating a positive sentiment and a net buy of approximately $2.23 million. The filing details multiple Engine Capital entities involved and clarifies their indirect beneficial ownership in the medical device company.
Engine capital funds acquire $2.23m of Orthofix Medical shares
Engine Capital Management has acquired approximately $2.23 million worth of Orthofix Medical Inc. (NASDAQ:OFIX) common stock between May 5 and May 7, 2026, totaling 185,896 shares. This strategic move, by a group that collectively owns over 10% of Orthofix, follows a 20% year-to-date decline in the stock and Orthofix's better-than-expected Q1 2026 earnings. The purchases suggest a value-seeking investment, with analysts predicting profitability for the medical device company this year.
Orthofix to Report First Quarter 2026 Financial Results
Orthofix Medical Inc. (OFIX) is set to report its First Quarter 2026 financial results. The article, delivered by Quantisnow, highlights that the company has recently reaffirmed its full-year 2026 financial guidance and provides details on recent analyst ratings and related SEC filings.
Orthofix Medical Inc. (NASDAQ:OFIX) Q1 2026 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ: OFIX) reported its Q1 2026 earnings, exceeding expectations with reported EPS of $-0.52 against an anticipated $-0.68. The company highlighted steady execution, improved stability, and reaffirmed its full-year 2026 guidance, expecting performance to accelerate through the year due to disciplined execution and upcoming product launches like VIRATA. Key drivers of growth included strong performance from top distributors, the 7D FLASH navigation system, and resilient Therapeutic Solutions and Global Limb Reconstruction businesses.
FDA Reclassifies Bone Growth Stimulators, Raising Competitive and Margin Pressures for Orthofix Medical
The FDA's reclassification of bone growth stimulators from Class III to Class II is expected to increase competition and pressure Orthofix Medical Inc.'s sales and margins. This regulatory change lowers barriers for new entrants, intensifying competition against Orthofix's current market-leading products and potentially impacting its financial performance. Despite these new risks, Wall Street maintains a Strong Buy consensus rating for OFIX stock.
Orthofix Medical Q1 Preview Shrinking Losses Test Bullish Profitability Narratives
Orthofix Medical (OFIX) reported narrowing losses in Q1 2026, with a basic EPS loss of US$0.06 and net income loss of US$2.2 million, following revenue growth and reduced quarterly losses in 2025. While bulls see shrinking losses as a sign of an earnings turnaround, bears highlight the company's 32.5% annual loss expansion over five years and a lower revenue growth forecast compared to the market. Despite a low P/S ratio and a valuation well below its DCF fair value, the company is not expected to be profitable within the next three years, raising concerns for investors.
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. The firm is encouraging current, long-term Orthofix shareholders to contact them to discuss legal options, which may include pursuing corporate governance reforms or the return of funds. They emphasize that shareholder involvement can enhance company policies, oversight, and overall shareholder value.
Orthofix Medical Reports 79.3% Wider Q1 2026 Loss at -$0.52/Share
Orthofix Medical Inc. (NASDAQ:OFIX) reported a Q1 2026 diluted loss of $0.52 per share, which was narrower than the analyst consensus of a $0.69 loss, despite being 79.3% wider year-over-year. Revenue for the quarter grew 1.6% to $196.7M, and a bright spot was 6.0% growth in Global Spine Fixation. The company provided full-year revenue guidance of $850.0M to $860.0M but did not update profitability targets, leading to a muted market response.
Orthofix Medical Posts Q1 2026 Growth, Narrows Losses
Orthofix Medical (OFIX) reported Q1 2026 results with modest sales growth and a reduction in net loss, signaling progress after completing major distributor transitions. The company reaffirmed its full-year 2026 guidance, projecting increased net sales and positive free cash flow. While an analyst maintains a Buy rating, TipRanks' AI Analyst, Spark, rates OFIX as Neutral due to current profitability concerns despite healthy gross margins and strong revenue growth.
Orthofix (NASDAQ: OFIX) posts Q1 2026 growth, narrows loss and maintains 2026 goals
Orthofix Medical Inc. (NASDAQ: OFIX) reported Q1 2026 results showing modest net sales growth of 1.6% (2.7% on a constant currency pro forma basis) and a narrowed GAAP net loss of $20.9 million, down from $53.1 million in Q1 2025. Despite a slight dip in non-GAAP pro forma adjusted EBITDA, the company reaffirmed its full-year 2026 guidance, projecting net sales of $850–$860 million and positive free cash flow, emphasizing improved commercial execution and margin initiatives.
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
Orthofix Medical Inc. reported first-quarter 2026 net sales of $196.7 million, with non-GAAP pro forma net sales increasing 3% year over year on a constant currency basis, excluding discontinued M6 product lines. The company reaffirmed its full-year 2026 financial guidance, anticipating improved execution and contributions from planned product launches. CEO Massimo Calafiore noted that distributor transitions are largely complete, positioning Orthofix for more consistent growth and margin expansion.
Orthofix: Q1 Earnings Snapshot
Orthofix Medical Inc. (OFIX) reported a first-quarter loss of $20.9 million, equating to 52 cents per share. After adjusting for non-recurring costs and stock option expenses, the loss was 12 cents per share. The medical device maker generated $196.7 million in revenue, with adjusted revenue at $196.4 million, and projects full-year revenue between $850 million and $860 million.
Orthofix: Q1 Earnings Snapshot
Orthofix Medical Inc. (OFIX) reported a first-quarter loss of $20.9 million, or 52 cents per share. Adjusted for non-recurring costs, the loss was 12 cents per share. The company posted revenue of $196.7 million and expects full-year revenue between $850 million and $860 million.
(OFIX) Movement Within Algorithmic Entry Frameworks
This article analyzes Orthofix Medical Inc. (OFIX) using algorithmic entry frameworks, highlighting weak near- and mid-term sentiment but a neutral long-term outlook. It identifies a strong risk-reward setup and provides specific institutional trading strategies (Long, Momentum Breakout, Short) with entry points, targets, and stop losses based on AI models. The analysis includes multi-timeframe signal assessments for support and resistance levels.
Orthofix Medical Inc expected to post a loss of 68 cents a share - Earnings Preview
Orthofix Medical Inc (OFIX) is projected to report a loss of 68 cents per share, according to an earnings preview. This announcement was made by Refinitiv and is based on their financial analysis.
[DEF 14A] Orthofix Medical Inc. Definitive Proxy Statement
Orthofix Medical Inc. has filed its definitive proxy statement (DEF 14A) for its annual meeting on June 10, 2026, outlining four key proposals for shareholder vote: electing ten directors, an advisory vote on executive compensation, ratifying EY as the 2026 auditor, and approving an amendment to its stock purchase plan. The company reported 2025 net sales of $822.3 million and a net loss of $(92.2) million, emphasizing its pay-for-performance compensation philosophy which resulted in below-target executive payouts due to missed financial goals. Shareholders previously showed strong support for executive compensation, with about 98% approval in 2025, and major institutional holders include Engine Capital Management and Juniper Investments Company.
Orthofix Medical (OFIX) Expected to Announce Earnings on Tuesday
Orthofix Medical (NASDAQ: OFIX) is scheduled to release its Q1 2026 earnings before market open on Tuesday, May 5th, with analysts anticipating a loss of ($0.29) per share and $193.275 million in revenue. The company previously reported ($0.06) EPS and $219.91 million in revenue, facing negative return on equity and net margin. Despite a current "Hold" consensus rating from analysts, insider transactions include a recent sale by Lucas Vitale and a purchase by Engine Capital, while institutional investors hold a significant stake in the medical device company.
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Orthofix Medical, Inc. (OFIX) following the termination of its CEO, CFO, and CLO in September 2023 for "inappropriate and offensive conduct." The investigation will focus on whether Orthofix's officers and/or directors breached their fiduciary duties or violated state or federal laws. This probe comes after a securities class action lawsuit was filed against the company regarding its failure to disclose material information.
How (OFIX) Movements Inform Risk Allocation Models
This article analyzes Orthofix Medical Inc. (OFIX) movements, highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies support being tested and an exceptional 71.7:1 risk-reward setup targeting an 18.0% gain. The piece also details three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles.
Orthofix to Report First Quarter 2026 Financial Results
Orthofix Medical Inc. (NASDAQ:OFIX) announced it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The company will host a conference call and webcast to discuss the results at 8:30 am Eastern Time on the same day. Interested parties can access the call via phone or webcast, and additional investor information is available on the company's website.
Orthofix CLO Jorge Cedron sells $47,985 in company stock By Investing.com
Orthofix Medical Inc.'s Chief Legal Officer, Jorge Andres Cedron, sold 3,743 shares of company stock for $47,985 on April 16, 2026, to cover tax withholding obligations. Despite the sale, which was a pre-approved "sell-to-cover" transaction, an InvestingPro analysis suggests Orthofix's stock is undervalued with positive earnings forecasts for fiscal 2026. The company recently exceeded Q4 2025 earnings and revenue expectations and announced strong preliminary Q1 2026 net sales.
Orthofix Medical (OFIX) CLO sells shares for RSU tax obligations
Jorge Andres Cedron, CLO of Orthofix Medical Inc. (OFIX), sold 3,743 shares of common stock at $12.82 per share on April 16, 2026. This sale was conducted solely to cover tax withholding obligations related to the settlement of restricted stock units (RSUs), as mandated by a pre-existing "sell-to-cover" requirement. Following the transaction, Cedron retains 59,006 shares, which includes 44,353 previously reported RSUs.
Orthofix CLO Jorge Cedron sells $47,985 in company stock
Orthofix Medical Inc.'s (NASDAQ:OFIX) Chief Legal Officer, Jorge Andres Cedron, sold 3,743 shares of company stock worth $47,985 to satisfy tax withholding obligations. This transaction was part of a pre-approved "sell-to-cover" requirement. Following the sale, Cedron directly holds 59,006 shares, including restricted stock units.
Orthofix reshuffles spine division leadership, posts preliminary Q1 sales
The provided article content is empty. A summary cannot be generated without content.
Orthofix CLO Jorge Cedron sells $47,985 in company stock
Orthofix CLO Jorge Cedron sold 3,743 shares of company stock worth $47,985 on April 16, 2026, to cover tax withholding obligations for restricted stock units. Following the transaction, Cedron directly holds 59,006 shares. Despite the sale, Orthofix appears undervalued with positive earnings forecasts, and the company recently reported a Q4 2025 EPS beat and restructured its spine division.
Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Rating of "Hold" by Brokerages
Orthofix Medical Inc. (NASDAQ:OFIX) has received a "Hold" consensus rating from six brokerage firms, with an average 12-month price target of $17.25 against its current trading price of $12.71. Despite some analyst upgrades and institutional buying, the company reported weak recent earnings with negative EPS and net margin, and analysts forecast negative EPS for the current fiscal year.
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Orthofix Medical, Inc. (OFIX) regarding potential breaches of fiduciary duties by its officers and directors. The investigation follows the termination of key executives in September 2023 due to "inappropriate and offensive conduct" and an ongoing securities class action lawsuit against the company. KSF is inviting long-term shareholders to come forward with information to assist their inquiry for potential legal action.
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Orthofix Medical, Inc. (NasdaqGS: OFIX) regarding potential breaches of fiduciary duties by its officers and directors. This follows the termination of key executives after an independent investigation revealed inappropriate conduct and a subsequent securities class action lawsuit against the company. KSF is inviting long-term shareholders or individuals with relevant information to contact them regarding their legal rights.
OFIX SEC Filings - Orthofix Med Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Orthofix Med (OFIX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms (Form 4). It highlights Orthofix's operations as a global medical technology company and explains what information can be found in their regulatory disclosures. The article also presents recent filings, such as an 8-K outlining non-GAAP metrics and several Form 4s detailing director stock grants.
Orthofix Medical (NASDAQ:OFIX) Receives Outperform Rating from Barrington Research
Barrington Research reiterated an "Outperform" rating for Orthofix Medical (NASDAQ:OFIX), setting a $17.00 price target that indicates a potential upside of approximately 36.9%. Despite a consensus "Hold" rating from other analysts, the stock has seen significant institutional and insider activity, including a large purchase by Engine Capital. Orthofix Medical, a global medical device company specializing in orthopedic and spinal solutions, reported negative earnings and margins, with analysts forecasting a negative EPS for the current year.
OFIX: Barrington Research Maintains Outperform Rating and Price Target | OFIX Stock News
Barrington Research has maintained its "Outperform" rating for Orthofix Medical (OFIX) with an unchanged price target of $17.00. This decision comes amidst varied analyst actions, including Stifel and Canaccord Genuity lowering their price targets while still holding "Buy" ratings. The average analyst target price for OFIX is $17.25, suggesting an upside of 38.89% from its current price, and GuruFocus estimates a one-year fair value of $15.83.
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical Inc. announced a strategic realignment of its Spine leadership team to accelerate profitable growth and improve execution. The company streamlined its Spine organization by eliminating the President, Global Spine Solutions role, with key leaders now reporting directly to the CEO. Orthofix also reported preliminary unaudited first-quarter 2026 net sales of approximately $196.7 million and reaffirmed its full-year 2026 guidance, expecting net sales between $850 million to $860 million.
Orthofix Medical (OFIX) Projects FY26 Adjusted EBITDA Between $95M and $98M
Orthofix Medical (OFIX) has projected its non-GAAP adjusted EBITDA for fiscal year 2026 to be between $95 million and $98 million, signaling a focus on financial performance and operational efficiencies. The company, which specializes in orthopedic and spine solutions, faces challenges such as negative revenue growth, operating, and net margins, and an Altman Z-Score indicating distress. Despite these issues, the company shows strong liquidity and manageable debt, with significant institutional and insider ownership, and recent insider buying suggesting confidence in its future.
Orthofix Realigns Spine Leadership to Strengthen Focus
Orthofix Medical Inc. has announced a strategic realignment of its spine business unit, which will involve changes to its leadership team including the appointment of a new president. This reorganization aims to strengthen the company's focus and execution in the competitive spine market, improving operational efficiency. The move reflects efforts to maintain its leading position amidst ongoing consolidation and pricing pressures in the medical device industry.
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical Inc. (NASDAQ: OFIX) has announced a strategic realignment of its Spine leadership team to accelerate profitable growth and enhance execution. The company reported preliminary unaudited net sales of approximately $196.7 million for the first quarter of 2026 and reaffirmed its full-year 2026 guidance, expecting net sales between $850 million to $860 million and non-GAAP adjusted EBITDA of $95 million to $98 million. The changes aim to streamline decision-making, strengthen accountability, and advance the commercialization of its 7D™ navigation platform.
